natgillin/translations-raw huggingface dataset:
at least a second type of host cell expressing on its surface an extracellular domain of a mutated form of said wt human PSMA, said mutated form comprising amino acids 1-750 of the amino acid sequence set forth in SEQ ID NO: 208; and at least a third type of host cell expressing on its surface an extracellular domain of wt rat PSMA comprising the amino acid sequence set forth in SEQ ID NO: 866; contacting said at least first, second and third types of host cells with a test bispecific single chain antibody comprising a first binding domain capable of binding to an epitope of human and/or primate CD3 on the surface of a T cell and a second binding domain capable of binding to the extracellular domain of human PSMA and an effector T cell; and 
vežuća domena, koja se može vezati na izvanstaničnu domenu kimere mutiranog ljudskog FAPa s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 448, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 i 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa divljeg tipa glodavca, no ne i na izvanstaničnu domenu FAPa divljeg tipa; vežuća domena, koja se može vezati na četiri Ig domene sa SEQ ID:436, cisteinom bogatu domenu sa SEQ ID:437 ili beta-lanac sema domene sa SEQ ID:438 izvanstanične domene c-MET; vežuća domena, koja se može vezati na mucinsku domenu sa SEQ ID:440, tri EGF-u slične domene sa SEQ ID:441 ili Sushi/SCR/CCP domenu sa SEQ ID:442 izvanstanične domene TEM1; i
The compound of Claim 1, wherein the crystalline form is Compound 1 free base hydrate, characterized by a powder X-ray diffraction pattern having at least one peak selected from those at 5.8, 7.6, 7.9, 10.7, 11.7, 14.0, 15.3, 15.8, 17.4, 18.3, 19.9, 20.4, 20.7, 22.5, 24.9, 25.8, and 26.7 degrees 2θ (pattern C), each peak being ± 0.2 degrees 2θ, when measured at about 25°C with Cu Ka radiation at 1.54178 Å. 
Spoj u skladu s patentnim zahtjevom 1, pri čemu je kristalni oblik slobodna baza hidrata Spoja 1, naznačen time, da ga karakterizira rendgenski difraktogram praha koji ima najmanje jedan pik odabran od sljedećih vrijednosti: 5.8, 7.6, 7.9, 10.7, 11.7, 14.0, 15.3 15.8, 17.4, 18.3, 19.9, 20.4, 20.7, 22.5, 24.9, 25.8 i 26.7 stupnjeva 2θ (uzorak C), pri čemu je svaki vrh ± 0.2 stupnjeva 2θ, izmjereno pri približno 25 °C uz Cu Ka zračenje na 1,54178 Å .
An anthranilamide compound represented by the formula (I) or its salt: wherein R1 is halogen, alkyl, haloalkyl, alkylcarbonyl or formyl; R2 is halogen, haloalkyl or haloalkoxy; R3 is halogen or haloalkyl; A is alkyl substituted by Y; Y is cyclopropyl which may be substituted by at least one substituent selected from the group consisting of halogen and alkyl; m is 1 or 2; n is 0 or 1; and q is 1, provided that when R1 is a fluorine atom, a chlorine atom, a bromine atom or methyl substituted at the 2-position of the benzene ring and another R1 is halogen substituted at the 4-position of the benzene ring, the halogen at the 4-position is a fluorine atom or a chlorine atom. 
Antranilamidni spoj, naznačen time, da je predstavljen formulom (Ia) ili sol istog: [image] pri čemu R1 je halogen ili alkil; svaki od R2 i R3 je halogen ili CF3; A je alkil supstituiran s Y; Y je ciklopropil koji može biti supstituiran s halogenom ili alkilom; m je 1 ili 2; n je 0 ili 1, pod uvjetom da kada je R1 atom fluora, atom klora, atom broma ili metil supstituiran na 2-om položaju benzenskog prstena i drugi R1 je halogen supstituiran na 4-om položaju benzenskog prstena, halogen na 4-om položaju je atom fluora ili atom klora.
is most preferably H or CH3. 
R> je najpoželjnije H ili CH.
A compound comprising: an amino acid sequence comprising Formula (I): 
(a) sekvencu aminokiseline koja sadrži formulu (1):
Ring A represents a benzene ring or a thiophene ring, 
(gdje, Prsten A predstavlja benzen-prsten ili tiofen-prsten,
A vaccine component comprising the immunogenic polypeptide of claim 9. 
Komponenta cjepiva koja sadrži imunogenski polipeptid prema zahtjevu 9.
The precipitate was filtered and the filtrate was evaporated. 
Talog se filtrira, a filtrat otpari.
The radioactive metal-labeled anti-cadherin antibody according to any one of claims 1 to 8, wherein the metal-chelating reagent is selected from the group consisting of isothiocyanobenzyl DOTA, methylisothiocyanobenzyl DTPA, and cyclohexylisothiocyanobenzyl DTPA. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je reagens za keliranje metala odabran iz skupine koju čine izotiocijanobenzil DOTA, metilizotiocijanobenzil DTPA i cikloheksilizotiocijanobenzil DTPA.
the compound mandipropamid. 
(B) spoj fluopiram.
The pharmaceutical depot according to claim 4, wherein the lactic acid-glycolic acid copolymer has a molar ratio of lactic acid:glycolic acid of 95:5. 
Farmaceutski depo prema patentnom zahtjevu 4, naznačen time što kopolimer mliječne kiseline i glikolne kiseline ima molarni odnos mliječne kiseline:glikolne kiseline od 95:5.
The wear member according to anyone of the preceding claims, characterized in that a marker (152) is provided adjacent the opening (101) to provide a visual indication to the operator when the lock (16) has been sufficiently tightened. 
Potrošni dio u skladu s patentnim zahtjevom 1, naznačen time što sadrži otvor (101) za prihvaćanje brave (16) radi osiguravanja potrošnog dijela (14) na podnožje (12).
wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; 
N R4 gdje: X predstavlja dva atoma vodika, atom sumpora, atom kisika ili C,.» alkilnu skupinu i atom vodika;
comparing at least a property of said fluid medium in said first region (6a) with at least the same property of said fluid medium in said second region (6b) or against a theroetical value of this property. 
- uspoređivanja u najmanju ruku svojstva navedenog fluidnog medija u navedenoj prvoj regiji (6a) s u najmanju ruku istim svojstvom navedenog fluidnog medija u navedenoj drugoj regiji (6b) ili s teorijskom vrijednošću tog svojstva.
The invention encompasses all kinds of possible interactions, such as for example mixing, brewing, extracting or dissolving. 
Ovaj izum obuhvaća sve vrste mogućih interakcija, takvih kao što su, na primjer, miješanje, vrenje, ekstrakcija ili otapanje.
Test item administration, 1 hour after the rotarod test 
- Primjena test primjerka, 1 sat nakon rotarod testa
or a pharmaceutically acceptable salt or solvate thereof, wherein: 
S SA ili njegova farmaceutski prihvatljiva sol ili solvat.
Where in formula (I), m or n are 2, the two substituents may be the same or different. 
Tamo gdje u formuli (1), m ili n su 2, dva supstituenta mogu biti jednaki ili različiti.
ET-743 is a complex chemical entity, as revealed by its structural features. 
ET-743 je kompleksan kemijski spoj, kao što je otkriveno prije njegovih strukturnih karakteristika.
The method of claim 8, wherein the persisting population of genetically engineered T cells comprises at least one cell selected from the group consisting of a T cell that was administered to the human, a progeny of a T cell that was administered to the human, and a combination thereof. 
T stanica za upotrebu prema patentnom zahtjevu 7, naznačena time što perzistentna populacija genetski konstruiranih T stanica sadrži najmanje jednu stanicu odabranu iz grupe koja se sastoji od T stanice koja je bila primijenjena kod čovjeka, potomstva T stanice koja je bila primijenjena kod čovjeka, i njihove kombinacije.
A method for implementing uplink resource indication, comprising: receiving, by a user terminal, an uplink resource grant indication (ul grant) carrying an uplink resource index from a base station, a corresponding relationship exists between the uplink resource index and at least one uplink subframe, and the corresponding relationship is determined by a uplink-downlink subframe ratio of a configuration, and the number of uplink subframes is more than the number of downlink subframes in the uplink-downlink subframe ratio of the configuration; 
Postupak za primjenu naznake resursa za uzlaznu vezu, koji se sastoji od: provođenja indeksa resursa za uzlaznu vezu u naznaci odobrenja resursa za uzlaznu vezu, odobrenja uzlazne veze, naznačen time da postoji odgovarajuća povezanost između indeksa resursa za uzlaznu vezu i barem jednog resursa za uzlaznu vezu (501, 502, 602, 603, 1101, 1102, 1202, 1203), te se odgovarajuća povezanost određuje sa uzlazno-silaznim odnosom podokvira konfiguracije, te je broj uzlaznih podokvira veći nego broj silaznih podokvira u uzlazno-silaznom odnosu podokvira konfiguracije; te slanja odobrenja uzlazne veze (503, 604, 1103, 1204).
In embodiments, the methods involve attaching an isosubstrate of an isoprenoid transferase to an active agent. In embodiments, the methods involve enzymatically reacting, with the isoprenoid transferase, the expressed protein and the active agent attached to the isosubstrate. 
(D vezanje izosupstrata izoprenoid transferaze na aktivno sredstvo; i (g) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu se eksprimirano antitijelo s aktivnim sredstvom veže na izosupstrat.
An antibody according to any one of embodiments 1 to 26 or the pharmaceutical composition of embodiment 29 for the treatment of plasma cell disorders like multiple myeloma or other B-cell disorders expressing BCMA. 
Antitijelo prema bilo kojem od zahtjeva 1 do 9 ili farmaceutska smjesa prema zahtjevu 12, naznačeni time, što se koriste kao lijek za liječenje poremećaja plazmocita kao što je multipli mijelom.
The host cell is preferably capable of producing ethanol, wherein most preferred yeasts include Saccharomyces cerevisiae, Pichia stipitis, Pachysolen tannophilus, or a methylotrophic yeast, preferably derived from the group of host cells comprising Pichia methanolica, Pichia pastoris, Pichia angusta, Hansenula polymorpha. It has surprisingly been found that the polypeptide according to the present invention and variants thereof can be expressed from yeast at high levels. "Yeast" shall herein refer to all lower eukaryotic organisms showing a unicellular vegetative state in their life cycle. 
(ii) stanica domaćina može proizvesti etanol, poželjno kvasac dobiven iz grupe a domaćina koje sadrže kvasac Saccharomyces cerevisiae, kvasac Pichia stipitis, kvasac Pachysolen tannophilus i/ili (ili) je stanica domaćina kvacac metilotrof, koji poželjno dolazi iz grupe stanica domaćina koje sadrže kvasac Pichia methanolica, Pichia pastoris, Pichia angusta, Hansenula polymorpha i/ili iv) je stanica domaćina filamentozni fungi koji je poželjno izabran iz stanica domaćina koje sadrže članove roda Trichoderma, Aspergillus, Chaetomium, Chrysosporium Penicillium or Acremonium, a još poželjnije su izabrane iz jedne od vrsta Trichoderma sp., Trichoderma reesei, Trichoderma longibrachiatum, Aspergillus niger, Aspergillus oryzae, Chaetomium thermophilum or Chrysosporium lucknowense.
Process according to claim 1, wherein the used oil comprises one or more oils selected from the group consisting of used hydraulic fluids, used gear oils, used system oils, used trunk piston engine oils, used turbine oils, used heavy duty diesel oils, used compressor oils and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da rabljeno ulje sadrži jedno ili više ulja koja su odabrana iz skupine koja sadrži rabljene hidrauličke fluide, rabljena ulja za mjenjače, rabljena ulja za sustave, rabljena motorna ulja tipa klipna motorna ulja, rabljena ulja za turbine, rabljena dizelska ulja za teške uvjete rada, rabljena ulja za kompresore i njihove smjese.
The mixture was left with magnetic stirring for 10 days. 
Smjesa je ostavljena uz magnetsko miješanje 10 dana.
The compound according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof, wherein A is an unsubstituted heteroaryl group or a heteroaryl group that is mono-substituted with a halogen atom, a C1 to C6 alkyl group optionally substituted with a halogen atom or a hydroxyl group, a C1 to C6 alkoxy group optionally substituted with a halogen atom or a hydroxyl group, a nitro group, a cyano group, or a group represented by the formula of -(O)p(CH2)mC(O)OR3 wherein R3 is a hydrogen atom or a C1 to C6 alkyl group, m is an integer of 0 to 2, and p is 0 or 1. 
Spoj prema bilo kojem od zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, naznačen time da je A nesupstituirana heteroaril skupina ili heteroaril skupina koja je mono supstituirana sa atomom halogena, C1 do C6 alkil skupinom proizvoljno supstituiranom s atomom halogena ili hidroksil skupinom, C1 do C6 alkoksi skupina proizvoljno supstituirana s atomom halogena ili hidroksil skupinom, nitro skupinom, cijano skupinom, ili skupinom prikazanom formulom –(O)p(CH2)mC(O)OR3, pri čemu je R3 atom vodika ili C1 do C6 alkil skupina, m je cijeli broj od 0 do 2 i p je 0 ili 1.
wherein the aryl and heteroaryl portion of aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-6alkoxy; heteroaryl optionally substituted with one to two substituents independently selected from the group consisting of C1-4alkyl, C1-4alkoxy, and carboxy; carboxy; C1-4alkoxycarbonyloxy; C1-4alkoxycarbonyl; aminocarbonyl; C1-4alkylaminocarbonyl; C3-6cycloalkylaminocarbonyl; hydroxy(C1-6)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; heterocyclylcarbonyl; cyano; halogen; trifluoromethoxy; and hydroxy; provided that no more than one R11 is heteroaryl (optionally substituted with one to two C1-4alkyl substituents); C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; or heterocyclylcarbonyl; 
Spoj formule (la) naznačen time da: R! je izabran iz skupine koju čine fenil(C;.g)alkil, piridiniKC,.s)alkil i furani(C,.3)alkil; pri čemu fenil, piridinil i furanil su proizvoljno supstituirani sa jednim do tri R' supstituenta nezavisno izabrana iz skupine koju čine je C1salkoksi; tetrazolil, Cs.gcikloalkilaminokarbonil; hidroksi(C1.4)alkilaminokarbonil; C4_,oarilaminokarbonil pri čemu Cs.qaril je proizvoljno supstituiran sa karboksi ili C,galkoksikarbonil; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi, metoksikarbonil; i karboksi; uz uvjet da ne više od jedan R!! je Csroarilaminokarbonil,;
C1-10 heteroaryl optionally substituted with 1 to 3 substituents on carbon independently selected from the group consisting of amino, C1-8 alkylamino, C1-9 amide, C1-4 alkyl, C1-4 alkoxy, cyano, halo, hydroxyl, oxo, trifluoromethyl, and trifluoromethoxy, and optionally substituted on a ring nitrogen with a C1-4 alkyl; and 
-10 heteroaril po izboru supstituiran s 1 do 3 supstituenata na ugljiku koji su neovisno odabrani iz skupine koju čine amino, C1-8 alkilamino, C1-9 amid, C1-4 alkil, C1-4 alkoksi, cijano, halo, hidroksil, okso, trifluorometil, i trifluorometoksi, i po izboru supstituiran na dušiku u prstenu s C1-4 alkilom; i
The system of claim 6, wherein the sheet (107) is an elastomeric sheet. A method, comprising: 
Sustav prema zahtjevu 6, naznačen time, da je pločica (107) jedna elastomerna pločica.
A compound according to claim 1, wherein the compound is 2-allyl-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-alil-4,5-dihidroksiizoftalonitril.
and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts. 
i/ili stereoizomerni oblik spoja s formulom I, i/ili smjese navedenih oblika, i/ili njihove farmaceutski prihvatljive soli.
with nucleoside kinase-deficient cells; 
(III) sa stanicama deficijentnim u nukleozid kinazi;
said antibody also comprises a hinge region comprising the amino acid sequence SEQ ID No. 
rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, također sadrži zglobnu regiju koja sadrži aminokiselinsku sekvenciju SEQ ID No.
The alcoholic beverage of claim 1, wherein at least 5 mole percent of the ethanol is a deuterated alcohol having the formula or or or the formula CD3CD2OH. 
Alkoholno piće prema patentnom zahtjevu 1, u kome najmanje 5 molarnih postotaka etanola predstavlja deuterirani alkohol koji ima formulu [image] ili [image] ili [image] ili formulu CD3CD2OH.
European patent application EP2295215A1 (Rudolf Meyer, publ. 
03.06.2014. Broj europske prijave patenta:
A refrigerating device comprising the composition according to any one of claims 1 to 15. 
Rashladni uređaj koji obuhvaća sastav iz bilo kojeg od zahtjeva 1 – 11.
The scratch resistant particles may be or comprise nanosized silica particles, preferably fused silica particles. The scratch resistant particles may be or comprise disc shaped particles, preferably having a width/thickness ratio exceeding 3:1, more preferably exceeding 5:1. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da čestice otporne na ogrebotine jesu ili sadrže čestice od silicijevog dioksida u obliku diska, koje imaju omjer širine/debljine veći ili jednak od 3:1, poželjnije veći ili jednak od 5:1.
A compound of formula (I) according to claim 1 wherein the optionally substituted aryl group is phenyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je izborno supstituirana arilna skupina fenil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
Use of (a) a B2 agonist as defined in any one of claims 1 and 3 to 7, for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 19 or 12. 
B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
333.4. The method of claim 14, wherein the melanoma is characterized by a mutation in B-RAF. 
Kruta oralna farmaceutska formulacija za uporabu prema zahtjevu 20 pri čemu je bolest naznačena time što ima mutaciju u B-RAF.
when linked to a nitrogen of the pyrazolyl ring is selected from hydrogen, methyl, fluoro-ethyl, ethyl and cyclopropyl; and R6 when linked to a carbon atom of the pyrazolyl ring is selected from hydrogen, hydroxy, methyl, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl; 
Ry kada je povezan na dušik od pirazolil-prstena, tada je odabran od sljedećih: vodik, metil, fluoro-etil, etil i ciklopropil; i Rg kada je povezan na atom ugljika od pirazolil-prstena, tada je odabran od sljedećih: vodik, hidroksi, metil, metoksi, cijano, trifluorometil, hidroksi-metil, halo, amino, fluoro-etil, etil i ciklopropil;
substituted and unsubstituted C1-3 alkyl. 
supstituirani i nesupstituirani C1-3alkil.
a crystalline zoledronic acid DL-lysine and water complex characterized by an X-ray powder diffraction pattern having peaks at about 8.3, 11.8, 12.3, 15.8, and 20.8 ±0.2 degrees two-theta; 
kompleks kristalne zoledronske kiseline, DL-lizina i vode naznačen time da ima uzorak rentgenske difrakcije praha koji ima maksimume kod oko 8.3, 11.8, 12.3, 15.8, i 20.8 ±0.2 stupnjeva dva-theta;
A method according to claim 1, wherein the solution obtained in step (iv) is mixed with the fat phase within 5 hours, packed in containers, and stored at about 4 to 10° C. for at least about 24 hours. 
Postupak prema bilo kojem od zahtjeva 1-5, gdje se otopina dobivena u koraku (iv) miješa s masnom fazom unutar 5 sati, poželjnije 2 sata, pakira u spremnike i poželjno čuva pri 4 do 10%C najmanje 24 sata.
A manufacturing method according to claim 1, wherein, in the electric excitation step, the voltage source is adapted for having a direct current i circulate through the support. 
Postupak za proizvodnju prema bilo kojem od zahtjeva 1 do 7, naznačen time što je, tijekom faze električnog pobuđivanja, izvor napona (33) prilagođen kako bi kroz nosač (5) prolazila istosmjerna struja.
The method for producing the compound of the formula (1) described in [2] above, using the compound of the formula (8) produced by: 
Postupak dobivanja spoja formule (1) u skladu s patentnim zahtjevom 1, naznačen time što se upotrebljava spoj formule (8), dobiven:
A method for treatment or prophylaxis of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, diabetic nephropathy, fibrotic disorders of the heart and dermatological fibroses comprising administering to a human an effective amount of the compound according to claim 6 . 
Spoj kako je definirano u bilo kojem od zahtjeva 1 do 11 naznačen time da je za uporabu u postupku za liječenje i/ili profilaksu zatajenja srca, plućne hipertenzije, kronične opstruktivne plućne bolesti, astme, zatajenja bubrega, nefropatije, fibroznih poremećaja unutarnjih organa i dermatoloških fibroza.
An aqueous agrochemical suspension comprising 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole as active ingredient, at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin, an inorganic thickener and a dispersant, wherein the at least one kind of alcohol comprises propylene glycol. 
PATENTNI ZAHTJEVI Vodena agrokemijska suspenzija koja sadrži 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5- dihidrooksazol kao aktivni sastojak, barem jednu vrstu alkohola odabranu iz grupe koja se sastoji od etilen glikola, propilen glikola 1 glicerina, neorgansko sredstvo za zgušnjavanje i disperzirajuće sredstvo, gdje barem jedna vrsta alkohola sadrži propilen glikol.
the Haemophilus influenzae type b antigen, in the form of polyribosylribitol phosphate conjugated to the tetanus protein (PRP-T), 
- antigen Haemophilus influenzae tipa b, u obliku poliribosilribitol fosfata konjugiran na protein tetanusa (PRP-T),
An edible product having a fat content of at least 15% by weight of dry matter, said fat consisting of 0-40 wt.% of dairy fat and 60-100 wt.% of the vegetable fat blend defined in any one of the preceding claims. 
Prehrambeni proizvod sa sadržajem masti od najmanje 15%, težinski, suhe tvari, naznačen time što navedena mast p i) čini 0-40%, težinski, mliječne masti i 60-100%, težinski, smjese biljnih masti, definirane u bilo kojem od prethodnih patentnih zahtjeva.
providing the prefabricated module (2) with pre-mounted engagement means for later engagement with prefabricated panels or slabs or other prefabricated modules by means of connecting devices, and 
(vi) pružajući prethodno proizvedeni modul (2) s prethodno montiranim sredstvima djelovanja za kasnije djelovanje s prethodno proizvedenim panelima ili pločama ili drugim prethodno proizvedenim modulima pomoću povezivanja uređaja, i
The process of claim 11, wherein 1 equivalent of the compound of formula 3b is combined with 1.1 equivalents of NH2OH-HCl in a 10:1 v/v mixture of THF/water. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da se 1 ekvivalent spoja formule 3b kombinira sa 1,1 ekvivalenta NH2OH-HCI u 10: 1 v/v mješavini THF / voda.